Careers
Contact Us

Company
Pipeline
Disease States
Science
Investors

Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility

Posted January 7, 2019 by CognitionDev

filed under: Nasdaq

In the News

Dec 31, 2020

Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Click to view full release

Dec 31, 2020

Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine

Click to view full release

Dec 8, 2020

Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation

Click to view full release

See All News

© 2021 Axsome Therapeutics, Inc. All rights reserved. 22 Cortlandt St, 16th Floor, New York, NY 10007 info@axsome.com

This modal has no inner div